The Journal of Experimental Medicine
Randox clinical diagnostic solutions
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents
Published online February 11, 2008
doi:10.1084/jem.20080136
The Journal of Experimental Medicine, Vol. 205, No. 2, 267-270
The Rockefeller University Press, 0022-1007 $30.00
© 2008 Dougan et al.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dougan, M.
Right arrow Articles by Dranoff, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dougan, M.
Right arrow Articles by Dranoff, G.
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Skin Cancer
Related Collections
Right arrowRelated Article
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

COMMENTARY

 Inciting inflammation: the RAGE about tumor promotion

Michael Dougan and Glenn Dranoff

M. Dougan and G. Dranoff are at Department of Medical Oncology and Cancer Vaccine Center, Dana-Farber Cancer Institute, and Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115

CORRESPONDENCE G.D.: glenn_dranoff{at}dfci.harvard.edu


ABSTRACT
Mechanisms of innate and adaptive immunity play a pivotal role in the development of cancer. Chronic inflammation can drive tumor development, but antitumor immunity can also restrict or even prevent tumor growth. New data show that feed-forward signals downstream of the receptor for advanced glycation end-products (RAGE) can fuel chronic inflammation, creating a microenvironment that is ideal for tumor formation.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Article

RAGE signaling sustains inflammation and promotes tumor development
Christoffer Gebhardt, Astrid Riehl, Moritz Durchdewald, Julia Németh, Gerhard Fürstenberger, Karin Müller-Decker, Alexander Enk, Bernd Arnold, Angelika Bierhaus, Peter P. Nawroth, Jochen Hess, and Peter Angel
J. Exp. Med. 2008 205: 275-285. [Abstract] [Full Text] [PDF]





  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS